Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310401 · ClinicalTrials.gov registry record · Phase 2
The Effect of Nebulized Albuterol on Donor Oxygenation
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 506
- Enrollment target
NCT00310401 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 506 participants.
The verdict
NCT00310401, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 506 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effectiveness of albuterol versus placebo with the following specific aims: a) Treatment of brain dead organ donors with albuterol will reduce pulmonary edema, improve donor oxygenation, and increase the number of lungs available for transplantation, b) Developing a blood test to predict the development of primary graft dysfunction in lung transplant recipients, and c) treating brain dead organ donors with albuterol will decrease markers of primary graft dysfunction and lead to improved lung transplant recipient outcomes and to higher rates of lungs suitable for transplantation.
Interventions
- DRUG Saline
- DRUG Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00310401
The ClinicalTrials.gov registry entry for NCT00310401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00310401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00310401 about?
NCT00310401 is a clinical study titled "The Effect of Nebulized Albuterol on Donor Oxygenation". The purpose of this study is to test the effectiveness of albuterol versus placebo with the following specific aims: a) Treatment of brain dead organ donors with albuterol will reduce pulmonary edema, improve donor oxygenation, and increase the number of lungs available for transplantation, b) Devel...
What is the current status of trial NCT00310401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 506 participants. The study started on 2007-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00310401?
The interventions under investigation include: Saline (DRUG), Albuterol (DRUG).
Who is sponsoring clinical trial NCT00310401?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.